AI Summary
Thinking
Thinking
We reviewed 2,508 live results for hizentra immune globulin subcutaneous human 20 liquid and narrowed them down to the 3 options that look most worth comparing first.
The options are Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid), Hizentra and XEMBIFY® (immune globulin subcutaneous, human–klhw) 20%.
Source: CSL Behring
Description
Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials.
Best for
primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment
Rate this product
Source: CSL Behring
Description
Hizentra is a 20% liquid subcutaneous immunoglobulin (SCIG) high-concentration formula designed for self-administration. It is indicated for Primary Humoral Immunodeficiency (PI) and as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its high concentration allows for lower infusion volumes compared to 10% products.
Best for
self-administration, home-based therapy, CIDP maintenance and high-concentration IgG
Rate this product
Source: Xembify
Description
XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration.
Best for
primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration
Rate this product
| Compare | #1Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) | #2Hizentra | #3XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% |
|---|---|---|---|
| Source | CSL Behring | CSL Behring | Xembify |
| Description | Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials. | Hizentra is a 20% liquid subcutaneous immunoglobulin (SCIG) high-concentration formula designed for self-administration. It is indicated for Primary Humoral Immunodeficiency (PI) and as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its high concentration allows for lower infusion volumes compared to 10% products. | XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration. |
| Best for | primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment | self-administration, home-based therapy, CIDP maintenance and high-concentration IgG | primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration |
| Action | CSL Behring | CSL Behring | Xembify |
| Rate this product |
"Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) from CSL Behring."
TopFind picked this because As the original manufacturer's product, Hizentra offers a high-concentration 20% formula that provides flexibility and independence for patients requiring long-term immune globulin therapy.
Note: TopFind AI compiles product and service information for general comparison purposes only.